BidaskClub lowered shares of FibroGen (NASDAQ:FGEN) from a strong-buy rating to a buy rating in a research note published on Tuesday morning.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of FibroGen from a sell rating to a hold rating in a research report on Tuesday, July 10th. Citigroup cut shares of FibroGen from a buy rating to a hold rating and set a $71.00 target price for the company. in a research report on Wednesday, August 8th. ValuEngine upgraded shares of FibroGen from a buy rating to a strong-buy rating in a research report on Thursday, June 21st. Mizuho restated a buy rating and issued a $74.00 target price on shares of FibroGen in a research report on Wednesday, August 8th. Finally, Leerink Swann set a $82.00 target price on shares of FibroGen and gave the company a buy rating in a research report on Tuesday, September 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $75.67.

NASDAQ FGEN opened at $49.79 on Tuesday. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.12 billion, a price-to-earnings ratio of -28.78 and a beta of 1.81. FibroGen has a 12-month low of $40.74 and a 12-month high of $68.55.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.31. The company had revenue of $43.95 million during the quarter, compared to analysts’ expectations of $28.70 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. On average, research analysts forecast that FibroGen will post -1.32 EPS for the current fiscal year.

In other news, Director Kalevi Kurkijarvi sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, July 19th. The shares were sold at an average price of $64.35, for a total value of $257,400.00. Following the completion of the transaction, the director now directly owns 27,700 shares in the company, valued at approximately $1,782,495. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $56.75, for a total transaction of $1,072,575.00. Following the completion of the transaction, the chief executive officer now owns 2,761,894 shares of the company’s stock, valued at $156,737,484.50. The disclosure for this sale can be found here. Insiders sold a total of 257,409 shares of company stock valued at $15,583,967 over the last 90 days. Corporate insiders own 8.96% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Emerald Advisers Inc. PA acquired a new position in FibroGen during the 2nd quarter worth approximately $22,954,000. Hillhouse Capital Management Ltd. increased its position in FibroGen by 3.2% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 2,686,196 shares of the biopharmaceutical company’s stock worth $168,156,000 after purchasing an additional 83,850 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in FibroGen by 20.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 469,708 shares of the biopharmaceutical company’s stock worth $29,404,000 after purchasing an additional 81,074 shares in the last quarter. Millennium Management LLC increased its position in FibroGen by 480.6% during the 1st quarter. Millennium Management LLC now owns 100,759 shares of the biopharmaceutical company’s stock worth $4,655,000 after purchasing an additional 83,404 shares in the last quarter. Finally, Boston Advisors LLC increased its position in FibroGen by 14.9% during the 2nd quarter. Boston Advisors LLC now owns 15,575 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 2,020 shares in the last quarter. Institutional investors and hedge funds own 76.06% of the company’s stock.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Read More: Bond

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.